Danirixin
Based on 9 publication(s) in Google Scholar
Danirixin is a selective, and reversible CXCR2 antagonist, with IC50?of?12.5 nM for CXCL8.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.19%
- CAS No.: 954126-98-8
- Formule: C19H21ClFN3O4S
- Masse moléculaire:441.90
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Endocrinology Compound Library
HY-L047
-
Anti-COVID-19 Compound Library
HY-L052
-
Orally Active Compound Library
HY-L061
-
Chemokine Compound Library
HY-L132
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Cytokine Inhibitors Library
HY-L161
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
Anti-Gastric Cancer Compound Library
HY-L184
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Lactylation Compound Library
HY-L249
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Clinical Compound Library
HY-L026
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Drug Repurposing Compound Library
HY-L035
Publications Citing Use of MedChemExpress (MCE) Danirixin
More- Nat Commun. 2025 Feb 17;16(1):1715. [Abstract]
- Cell Death Dis. 2019 Mar 20;10(4):273. [Abstract]
- Environ Int. 2026 Feb:208:110085. [Abstract]
- Cancer Cell Int. 2021 Jul 3;21(1):337. [Abstract]
- Front Immunol. 2021 May 7:12:667177. [Abstract]
- Int J Mol Sci. 2023 Nov 27;24(23):16803. [Abstract]
- Int Immunopharmacol. 2021 Jun:95:107153. [Abstract]
- University of Regensburg. 2025 Dec 3.
- Research Square Preprint. 2021 Mar.
Activité biologique
|
CXCL8-CXCR2 12.5 nM (IC50) |
Danirixin is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 954126-98-8
-
Appearance Solid
-
Masse moléculaire 441.90
-
Formule C19H21ClFN3O4S
-
Color White to off-white
-
SMILES
O=C(NC1=CC=C(Cl)C(S([C@H]2CCCNC2)(=O)=O)=C1O)NC3=C(C)C(F)=CC=C3
-
Synonyms
GSK1325756
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
The CXCL8/MAPK/hnRNP-K axis enables susceptibility to infection by EV-D68, rhinovirus, and influenza virus in vitro. [Abstract]2025 Feb 17;16(1):1715. PMID: 39962077 -
Cell Death Dis
Cancer-associated fibroblasts enhance tumor-associated macrophages enrichment and suppress NK cells function in colorectal cancer. [Abstract]2019 Mar 20;10(4):273. PMID: 30894509 -
Environ Int
Di-n-butyl phthalate induces NF-κB-mediated senescence-associated secretory phenotype to promote epithelial proliferation, epithelial-mesenchymal transition, and benign prostatic hyperplasia. [Abstract]2026 Feb:208:110085. PMID: 41621134 -
Cancer Cell Int
SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness. [Abstract]2021 Jul 3;21(1):337. PMID: 34217295 -
Front Immunol
CXCL8 Associated Dendritic Cell Activation Marker Expression and Recruitment as Indicators of Favorable Outcomes in Colorectal Cancer. [Abstract]2021 May 7:12:667177. PMID: 34025668 -
Int J Mol Sci
CXCR2-Blocking Has Context-Sensitive Effects on Rat Glioblastoma Cell Line Outgrowth (S635) in an Organotypic Rat Brain Slice Culture Depending on Microglia-Depletion (PLX5622) and Dexamethasone Treatment. [Abstract]2023 Nov 27;24(23):16803. PMID: 38069130 -
Int Immunopharmacol
Tumor-associated macrophages-mediated CXCL8 infiltration enhances breast cancer metastasis: Suppression by Danirixin. [Abstract]2021 Jun:95:107153. PMID: 33677254 -
-
Solvant et solubilité
DMSO : 100 mg/mL (226.30 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (11.31 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2630 mL | 11.3148 mL | 22.6296 mL | 56.5739 mL |
| 5 mM | 0.4526 mL | 2.2630 mL | 4.5259 mL | 11.3148 mL | |
| 10 mM | 0.2263 mL | 1.1315 mL | 2.2630 mL | 5.6574 mL | |
| 15 mM | 0.1509 mL | 0.7543 mL | 1.5086 mL | 3.7716 mL | |
| 20 mM | 0.1131 mL | 0.5657 mL | 1.1315 mL | 2.8287 mL | |
| 25 mM | 0.0905 mL | 0.4526 mL | 0.9052 mL | 2.2630 mL | |
| 30 mM | 0.0754 mL | 0.3772 mL | 0.7543 mL | 1.8858 mL | |
| 40 mM | 0.0566 mL | 0.2829 mL | 0.5657 mL | 1.4143 mL | |
| 50 mM | 0.0453 mL | 0.2263 mL | 0.4526 mL | 1.1315 mL | |
| 60 mM | 0.0377 mL | 0.1886 mL | 0.3772 mL | 0.9429 mL | |
| 80 mM | 0.0283 mL | 0.1414 mL | 0.2829 mL | 0.7072 mL | |
| 100 mM | 0.0226 mL | 0.1131 mL | 0.2263 mL | 0.5657 mL |
Danirixin Related Classifications
HY-19768 Related Classifications
Powered by Bioz